[摘要] 目的 探討奧美拉唑、伊托必利和鋁鎂加聯合治療反流性食管炎的臨床療效。方法 將53例反流性食管炎患者隨機分為對照組(26例)和觀察組(27例)，對照組予口服奧美拉唑、伊托必利等綜合治療，觀察組在對照組綜合治療的基礎上加服鋁鎂加混懸液15mL，3次/d，於治療8周後複查胃鏡，觀察鏡下治愈率。結果 對照組內鏡下治愈率為65.4%，觀察組內鏡下治愈率為92.6%，兩組比較有統計學意義(P
[關鍵詞] 反流性食管炎； 胃食管反流病； 奧美拉唑； 伊托必利； 鋁鎂加
[中圖分類號] R571 [文獻標識碼] A [文章編號] 1673-9701(2010)03-155-02
Combination of Omeprazole，Itopride and Almagate for Reflux Esophagitis
SHI Rongjie YANG Liwei WU Zesheng HE Fang
NO.2 Department of Internal Medicine，the Affiliated Hospital of Dali University，Dali 671000，China
[Abstract] ObjectiveTo evaluate the effects of Omeprazole combined with Itopride and Almagate in the treatment of reflux esophagitis. MethodsFifty-three cases of reflux exsophagitis were randomly divided into two groups：observation group (n=27)and control group(n=26). Both groups were given Omeprazole and Itopride，and Almagate suspension was added to the observation group(n=27)15ml(3 times a day)，and at the end of 8-week treatment，the curative rate was rechecked by endoscope. ResultsThe curative rate under endoscope was 65.4% in the control group and 92.6% in the observation group，respectively，and the difference between the two groups was significant(P
[Key words]Reflux esophagitis； Gastroesophageal reflux disease； Omeprazole； Itopride； Almagate
反流性食管炎(reflux esophagitis，RE)是指因食管胃連接部防反流機構障礙而導致胃或腸內容物反流入食管，從而引起食管炎症，也有人稱之為胃食管反流病(gastroesophageal reflux disease，GERD)[1]。自2006年1月起，筆者對RE患者在口服奧美拉唑、伊托必利等綜合治療的基礎上加服鋁鎂加混懸液，取得較好療效，現報道如下。
1 資料與方法
1.1 一般資料
選擇RE患者共53例，其中男35例，女18例，平均年齡(45.8±18.6)歲。將53例患者隨機分為對照組和觀察組，兩組在臨床表現、內鏡檢查及分級等方麵比較差異均無統計學意義(P>0.05)，具有可比性，見表1。